Investors sentiment increased to 1.51 in 2018 Q2. Its up 0.32, from 1.19 in 2018Q1. It improved, as 31 investors sold Cambrex Corporation shares while 51 reduced holdings. 37 funds opened positions while 87 raised stakes. 32.93 million shares or 1.56% more from 32.42 million shares in 2018Q1 were reported.
Ontario – Canada-based Ontario Teachers Pension Plan Board has invested 0.01% in Cambrex Corporation (NYSE:CBM). Palouse Capital Mgmt invested in 0.1% or 5,896 shares. Gotham Asset Management Ltd Llc has 85,215 shares for 0.06% of their portfolio. Glenmede Na holds 344 shares or 0% of its portfolio. Moreover, Kbc Nv has 0% invested in Cambrex Corporation (NYSE:CBM). Cubist Systematic Strategies Limited Company has 0.01% invested in Cambrex Corporation (NYSE:CBM). Moreover, Loomis Sayles & Commerce L P has 0.05% invested in Cambrex Corporation (NYSE:CBM) for 460,500 shares. Polaris Mngmt Ltd Liability Company, Massachusetts-based fund reported 43,597 shares. Counselors Of Maryland Llc reported 464,112 shares. Victory Capital Incorporated holds 0% in Cambrex Corporation (NYSE:CBM) or 5,265 shares. Northern Tru Corporation holds 587,145 shares. 10,340 were accumulated by Aperio Group Llc. Natixis Advsr L P reported 50,639 shares. Prudential owns 91,923 shares or 0.01% of their US portfolio. Regions Corp invested in 0% or 194 shares.
Since June 11, 2018, it had 0 insider purchases, and 5 insider sales for $10.70 million activity. Vadaketh Tom George sold 9,510 shares worth $603,098.
The stock of Cambrex Corporation (NYSE:CBM) registered an increase of 1.82% in short interest. CBM’s total short interest was 4.03M shares in November as published by FINRA. Its up 1.82% from 3.96M shares, reported previously. With 271,500 shares average volume, it will take short sellers 15 days to cover their CBM’s short positions.
The stock increased 1.61% or $0.76 during the last trading session, reaching $47.85. About 393,147 shares traded or 1.48% up from the average. Cambrex Corporation (NYSE:CBM) has risen 30.46% since November 14, 2017 and is uptrending. It has outperformed by 14.84% the S&P500.
Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.61 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 13.14 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.
More important recent Cambrex Corporation (NYSE:CBM) news were published by: Seekingalpha.com which released: “Follow-Up Analysis Supporting Cambrex Short Thesis” on October 16, 2018, also Globenewswire.com published article titled: “Cambrex Reports Third Quarter 2018 Financial Results”, Seekingalpha.com published: “Cambrex Corporation (CBM) CEO Steven Klosk on Q3 2018 Results – Earnings Call Transcript” on November 11, 2018. More interesting news about Cambrex Corporation (NYSE:CBM) was released by: Streetinsider.com and their article: “Cambrex Corporation (CBM) PT Lowered to $60 at Stephens Following 3Q” with publication date: November 12, 2018.